Research on chemotherapy and its side effects. Covers nerve-injury prevention, gold-nanorod therapy, less-intensive regimens, and combination treatments.
Research suggests that palliative chemotherapy can lead to more invasive medical procedures and a higher risk of death in intensive care units among advanced cancer patients. The findings highlight the need for clearer discussion of the harms and benefits of palliative chemotherapy at the end of life.
Research finds that chemotherapy induces epigenetic changes in breast cancer patients' blood cells, leading to inflammation and symptoms like fatigue. The study identifies eight sites of methylation altered by chemotherapy, correlating with increased inflammatory signaling proteins.
Research suggests that terminally ill cancer patients who receive chemotherapy in the last months of life are more likely to undergo intensive medical care and die in an intensive care unit. The study highlights the importance of end-of-life discussions between patients and physicians.
Researchers are exploring innovative approaches, including medication like Bevacizumab and handheld optical coherence tomography, to improve vision in young children with optic pathway gliomas. These treatments have shown promising results, offering improved visual acuity and stability.
Researchers developed nanoparticles that absorb energy from infrared red wavelength and release chemotherapy drugs when triggered by two-photon laser. The delivery system shows promise for treating cancer with reduced treatment side effects and increased cancer-killing effect.
Researchers from the University of Surrey launch eSMART, a programme using mobile phone technology to remotely monitor patients undergoing chemotherapy for breast, bowel and blood cancers. The system assesses symptoms and triggers alerts to doctors or nurses within minutes.
Researchers at Tel Aviv University propose a new nanoscale drug-delivery system to tackle aggressive ovarian cancer using a cluster of nanoparticles called gagomers. The system accumulates in tumors, producing dramatic therapeutic benefits and reducing toxic accumulation in healthy organs.
A multi-site research project led by Dr. Bradley J. Monk found that women with advanced cervical cancer live an average of 17 months longer when combined with bevacizumab and chemotherapy compared to chemotherapy alone. The study reveals a significant improvement in treatment outcomes for patients with metastatic cervical cancer.
Researchers discovered a new drug, spironolactone, that inhibits DNA repair mechanisms, making cancer cells more susceptible to chemotherapy. This finding has the potential to enhance cancer treatment protocols and improve patient outcomes.
A study of 285 stage III-IV SCCOP patients found that HPV-positive patients developed distant metastases later, in more subsites, and atypical sites compared to HPV-negative patients. The most common sites were lung and bone for both groups.
Researchers have developed a biologic drug that prevents the production of HE4 protein, allowing ovarian cancer cells to grow aggressively and resist chemotherapy. The novel biologic has shown promising results in cell and animal models, increasing the potential for improved treatment and survival rates for women with ovarian cancer.
A new treatment approach has been proposed to prevent intestinal inflammation in cancer patients. Researchers suggest using IL-1b beta blocking reagents, such as Anakinra, to alleviate mucositis, a common side effect of chemotherapy and irradiation.
Researchers have developed 'smart' gold nanoshells that target cancer cells specifically, delivering anticancer drugs and converting near-infrared light into heat. This breakthrough could lead to more effective cancer treatments by overcoming the limitation of traditional chemotherapy techniques.
Researchers at the University of Adelaide found that grape seed extract improves chemotherapy's potency and reduces intestinal damage in laboratory studies. Grape seed extracts showed no side effects on healthy intestine, decreased inflammation by up to 55%, and increased growth-inhibitory effects on colon cancer cells.
Researchers discovered that altering chemotherapy drugs to react only with palladium could minimize damage to healthy cells. By implanting devices coated with palladium into tumours, the drugs would become activated only where needed, potentially reducing side effects.
Researchers at NYU Langone Health have found a biological weakness in mutant K-Ras, the most commonly mutated gene involved in human cancers. By blocking the activity of related genes H-Ras and N-Ras, chemotherapy drug irinotecan can stall tumor growth.
A 10.4-year median follow-up study by EORTC trial 22921 found that adjuvant chemotherapy does not improve survival or disease-free survival for cT3-resectable T4 M0 rectal cancer patients, highlighting the need for new treatment strategies.
Scientists at Weill Cornell Medical College have found that a twice-daily pill, idelalisib, can turn deadly blood cancer into a highly treatable disease. The study suggests that patients with CLL may avoid debilitating chemotherapy, leading to significant side effects and death.
Researchers found that chronic preoperative pain, chemotherapy, and depression were linked to persistent pain in breast cancer patients 12 months post-surgery. The study included over 800 women with nonmetastasized breast cancer treated between 2006-2010.
A new study from the University of Michigan Comprehensive Cancer Center found that surgery significantly improves survival rates and functional outcomes for patients with advanced oral cavity cancer. In contrast, those who received chemotherapy after initial treatment had poorer results.
A phase III clinical trial found that switching to a different chemotherapy did not improve overall survival or time to progression for women with metastatic breast cancer and elevated circulating tumor cells. Patients with low CTCs before starting chemotherapy had a median overall survival of 35 months, while those with elevated CTCs ...
A phase III clinical trial presented at the 2013 San Antonio Breast Cancer Symposium found that bisphosphonate zoledronate had no effect on event-free survival in women with chemoresistant breast cancer. Researchers also reported that patients with hormone receptor-positive disease were more common, which may impact treatment outcomes.
A randomized, phase II clinical trial found that adding carboplatin and/or bevacizumab to standard presurgery chemotherapy increased the number of patients with no residual cancer detected at surgery. The study showed significant increases in pathologic complete response rates for patients treated with these combinations.
A new trial found that adding chemotherapy carboplatin and the molecularly targeted drug veliparib to standard presurgery chemotherapy improved pathologic complete response rates for patients with triple-negative breast cancer. The study's adaptive design showed a 92% predictive probability of success in a phase III trial.
A nationwide study found that adding carboplatin to standard chemotherapy significantly increased tumor shrinkage in patients with triple-negative breast cancer. The results suggest that carboplatin could be used as an alternative or addition to current treatments.
A new CRISPR approach enables researchers to study the entire genome at once, identifying genes essential for cell survival and potential cancer-causing genes. The technology could lead to more efficient and reliable alternatives to RNA interference, enabling targeted cancer treatments.
Researchers found that women with HER2-positive breast cancer who had high levels of immune cells in their tumors gained the most benefit from presurgery treatment with chemotherapy and trastuzumab. This biomarker can help identify patients most likely to benefit from this therapy.
A new gene sequencing project identifies a family of drugs that enhance oxidative stress to kill rhabdomyosarcoma tumor cells and boost chemotherapy effectiveness. The study offers hope for treating this aggressive childhood cancer, particularly for patients with recurrent disease.
A nationwide study led by Children's Mercy researcher found that adding a monoclonal antibody called gemtuzumab to standard chemotherapy significantly reduced the risk of relapse and increased disease-free survival rates in children with acute myeloid leukemia (AML). The treatment was most effective in patients at high risk of relapse.
Medical researchers at the University of Alberta found that one chemotherapy drug prevents another from working, making combination therapy ineffective. This discovery will guide oncologists on how to combine or avoid certain drugs, ultimately leading to better treatment options for patients.
A study led by Beth Israel Deaconess Medical Center researchers found that carbon monoxide can prevent tumor growth and amplify chemotherapy's effects, sparing healthy tissue. The findings suggest CO induces an 'anti-Warburg' effect, fueling cancer cell bioenergetics until metabolic exhaustion.
Scientists from the University of Granada have developed a technique that uses circulating tumour cells and genetic markers to predict patient response to chemotherapy. This study has been awarded at the 9th International Symposium on Minimal Residual Cancer in Paris.
The study shows that cyclophosphamide's effectiveness is enhanced by the immune response triggered by certain beneficial gut bacteria. The intestinal microbiota plays a crucial role in modulating the anticancer immune effects of chemotherapy.
A groundbreaking discovery in 1993 led to the development of a cancer treatment, Erivedge, which targets the hedgehog signaling pathway. The breakthrough was made by researchers investigating fundamental mechanisms regulating vertebrate brain development.
A new multicenter study emphasizes the importance of a standardized treatment plan for patients with advanced bladder cancer. The research, involving eight Italian centers, found that response rates and outcomes for salvage therapies are dismal, with no clearly established second-line therapy.
A study led by St. Jude Children's Research Hospital found that combining gemtuzumab ozogamicin with conventional chemotherapy improves the outcome of bone marrow transplantation for some children with high-risk acute myeloid leukemia. The treatment helped eliminate minimal residual disease, leading to better patient survival rates.
Researchers developed a new drug-delivery technique using two types of nanoparticles to effectively treat pancreatic cancer in mouse models. The dual-wave method opens up access to tumor cells, allowing chemotherapy drugs to target and kill cancer cells more efficiently.
A new study from MIT biologists found that tumor cells with mutated p53 can be made more vulnerable to chemotherapy by blocking the MK2 gene. In a study of mice, tumors lacking both p53 and MK2 shrank dramatically when treated with the drug cisplatin.
A new clinical trial found that low-intensity chemotherapy regimens are highly effective in treating adult patients with Burkitt lymphoma, resulting in excellent long-term survival rates of over 90%. The treatment reduces toxicity compared to standard high-dose chemotherapy, leading to improved outcomes for adults.
Researchers have discovered a new method of delivering chemotherapy drugs directly to brain tumours using a polymer originally designed to mend broken bones. The therapy has shown promising results, reducing toxic side effects and potentially leading to more effective treatment and prolonged patient survival.
Researchers at Northwestern University have successfully tested a nontoxic therapy that suppresses Lupus in blood samples of people with the autoimmune disease. The study found that the peptides can block and reduce autoantibody production to almost baseline levels, showing potential as a vaccine-like therapy.
Researchers found that Oxantel inhibits biofilm formation by targeting an enzyme crucial for bacterial growth, offering a potential therapy for periodontitis. Periodontitis is linked to various health risks, including diabetes, heart disease, and certain cancers.
The EORTC trial found that perioperative chemotherapy with FOLFOX4 increases progression-free survival compared to surgery alone, but no significant difference in overall survival was observed. The study concludes that perioperative chemotherapy should remain the reference treatment for patients with resectable liver metastases from co...
Researchers used advanced imaging techniques to determine which patients with glioblastoma would benefit from anti-angiogenic drugs. Persistent improvement in vessel perfusion and oxygen delivery was found to be associated with longer survival rates among patients.
Researchers at CWRU aim to build nanoparticles that can infiltrate and quash aggressive cancers that survive traditional therapy. They will perfect molecular coatings called ligands to enable nanochains to home in on micrometastases.
Glen J. Weiss, MD, presents studies on TSR-011, a potent ALK and TRK inhibitor, and Ki67, a measure of cell proliferation, in non-small cell lung cancer (NSCLC) tumors collected before chemotherapy and after surgery. These studies show preliminary clinical activity against various tumor types.
A study found that early stem cell transplants significantly improved remission rates among high-risk non-Hodgkin's lymphoma patients. However, the treatment did not impact overall survival for this group, except in those with the highest risk of relapse.
Researchers have developed a novel nanostructure that can carry multiple components for simultaneous detection, diagnosis, and targeted drug delivery to cancer cells. This Janus nanostructure has the potential to provide earlier diagnosis and more accurate targeting of cancer cells, reducing drug side effects.
Researchers found metformin as an effective radiosensitizer for treating stage III non-small cell lung cancer, improving local control and overall survival. The study suggests combining metformin with chemotherapy and radiation therapy may be a promising treatment approach.
The EORTC/GIMEMA 06012 trial found sequential combination of gemtuzumab ozogamicin (GO) and standard chemotherapy has no benefit for older patients with acute myeloid leukemia. GO is too toxic for patients over 70 years old, whereas younger patients may potentially benefit from such treatment.
Researchers at Oregon State University developed a nanotech system that combines heat and chemotherapeutic drugs to kill 95% of ovarian cancer cells. The system uses iron oxide nanoparticles coated with a cancer-killing drug, which are heated using an oscillating magnetic field, improving efficacy while minimizing side effects.
A new study found that targeted treatment and conventional chemotherapy can be effective in treating ovarian cancer, particularly in women with BRCA gene mutations. The treatment combination showed promising results in patients who had previously developed resistance to PARP inhibitor drugs.
Treatment with gemcitabine for 6 months significantly improved overall survival (22.8 months vs. 20.2 months) and disease-free survival (13.4 months vs. 6.7 months) in patients after pancreatic cancer surgery. The study demonstrated a 10.3% increase in 5-year overall survival rate.
Researchers found a 12.6% false-negative rate with SLN surgery, exceeding the prespecified threshold for patient selection. The study suggests that greater sensitivity is needed to support the use of SLN surgery as an alternative to ALND in patients with cN1 disease.
Chemists at Scripps Research Institute develop new technique to create more stable antibody-drug conjugates, reducing toxicity and increasing efficacy. The new method uses a novel Thiol-Click reaction to form stronger linkages with cysteine amino acids.
A Loyola University Medical Center study found that the active ingredient of ipecac syrup effectively inhibits bladder cancer cell growth, especially when combined with cisplatin. The compound has little effect on normal cells and may offer a new treatment option for patients with advanced bladder cancer.
Researchers have discovered a key signal that keeps oocytes alive: coenzyme A, which maintains enzyme CaMKII on, preventing cell death. This mechanism appears to be conserved in animals, offering potential therapies for preserving women's egg supply and fertility.
Researchers found that two benign strains of C. difficile can prevent infection by more dangerous strains. The harmless strains occupy the same niches as the infective strains, preventing colonization and ultimately infection. This study provides promising results for developing new protective measures against C. difficile infection.
A clinical trial found that cediranib, a biological therapy, extended the time before ovarian cancer recurred and increased overall survival by up to 30% compared to chemotherapy alone. The treatment showed incremental improvements in progression-free and overall survival.
Researchers at Johns Hopkins have discovered that a chemical commonly used as a dog food preservative, ethoxyquin, may prevent the painful nerve damage found in cancer patients taking chemotherapy drug Taxol. The study shows that adding ethoxyquin to mice prevented two-thirds of nerve degeneration caused by Taxol.